Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...

Utrophin increase in muscle cells after transcriptional adaptation normalises cell function in Duchenne muscular dystrophy ...

Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...

The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD ... a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein ...

New York, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association ... appear in childhood or early adulthood. In total, mutations in over 100 known genes can cause different forms ...